Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Ligand with two modes of interaction with the dopamine D2 receptor-an induced-fit mechanism of insurmountable antagonism

  • Ågren, Richard
  • Zeberg, Hugo
  • Stepniewski, Tomasz Maciej, 1988-
  • Free, R. Benjamin
  • Reilly, Sean W.
  • Luedtke, Robert R.
  • Århem, Peter
  • Ciruela, Francisco
  • Sibley, David R.
  • Mach, Robert H.
  • Selent, Jana
  • Nilsson, Johanna
  • Sahlholm, Kristoffer
A solid understanding of the mechanisms governing ligand binding is crucial for rational design of therapeutics targeting the dopamine D2 receptor (D2R). Here, we use G protein-coupled inward rectifier potassium (GIRK) channel activation in Xenopus oocytes to measure the kinetics of D2R antagonism by a series of aripiprazole analogues, as well as the recovery of dopamine (DA) responsivity upon washout. The aripiprazole analogues comprise an orthosteric and a secondary pharmacophore and differ by the length of the saturated carbon linker joining these two pharmacophores. Two compounds containing 3- and 5-carbon linkers allowed for a similar extent of recovery from antagonism in the presence of 1 or 100 μM DA (>25 and >90% of control, respectively), whereas recovery was less prominent (∼20%) upon washout of the 4-carbon linker compound, SV-III-130, both with 1 and 100 μM DA. Prolonging the coincubation time with SV-III-130 further diminished recovery. Curve-shift experiments were consistent with competition between SV-III-130 and DA. Two mutations in the secondary binding pocket (V91A and E95A) of D2R decreased antagonistic potency and increased recovery from SV-III-130 antagonism, whereas a third mutation (L94A) only increased recovery. Our results suggest that the secondary binding pocket influences recovery from inhibition by the studied aripiprazole analogues. We propose a mechanism, supported by in silico modeling, whereby SV-III-130 initially binds reversibly to the D2R, after which the drug-receptor complex undergoes a slow transition to a second ligand-bound state, which is dependent on secondary binding pocket integrity and irreversible during the time frame of our experiments., This study was supported by grants from Stiftelsen Lars Hiertas Minne, Åhlénstiftelsen, Karolinska Institutet Funds and Magnus Bergvalls stiftelse (to K.S.). K.S. received postdoctoral grants from the Swedish Brain Foundation and the Swedish Society of Medicine and is currently a fellow at the Wallenberg Center for Molecular Medicine at Umeå University. T.M.S. acknowledges financial support from the National Science Centre of Poland, project number 2017/27/N/NZ2/02571. J.S. received financial support from the Instituto de Salud Carlos III FEDER (PI15/00460 & PI18/00094) and the NEURON-ERANET (AC18/00030). F.C. was supported by FEDER/Ministerio de Ciencia, Innovación y Universidades–Agencia Estatal de Investigación (SAF2017-87349-R) and the Catalan government (2017 SGR 1604). R.B.F. and D.R.S. are supported by the National Institutes of Health, National Institute of Neurological Disorders and Stroke-Intramural Research Program (ZIA NS002263). We would like to thank Brittney Miller and Martin Dalefield for excellent technical assistance.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Ecto-GPR37: a potential biomarker for Parkinson's disease

  • Morató, Xavier
  • Garcia-Esparcia, Paula
  • Argerich, Josep
  • Llorens, Franc
  • Zerr, Inga
  • Paslawski, Wojciech
  • Borràs, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Petäjä-Repo, Ulla E.
  • Fernández-Dueñas, Víctor
  • Ferrer, Isidre
  • Svenningsson, Per
  • Ciruela, Francisco
Objective: α-Synuclein has been studied as a potential biomarker for Parkinson's disease (PD) with no concluding results. Accordingly, there is an urgent need to find out reliable specific biomarkers for PD. GPR37 is an orphan G protein-coupled receptor that toxically accumulates in autosomal recessive juvenile parkinsonism. Here, we investigated whether GPR37 is upregulated in sporadic PD, and thus a suitable potential biomarker for PD. Methods: GPR37 protein density and mRNA expression in postmortem substantia nigra (SN) from PD patients were analysed by immunoblot and RT-qPCR, respectively. The presence of peptides from the N-terminus-cleaved domain of GPR37 (i.e. ecto-GPR37) in human cerebrospinal fluid (CSF) was determined by liquid chromatography-mass spectrometric analysis. An engineered in-house nanoluciferase-based immunoassay was used to quantify ecto-GPR37 in CSF samples from neurological control (NC) subjects, PD patients and Alzheimer's disease (AD) patients. Results: GPR37 protein density and mRNA expression were significantly augmented in sporadic PD. Increased amounts of ecto-GPR37 peptides in the CSF samples from PD patients were identified by mass spectrometry and quantified by the in-house ELISA method. However, the CSF total α-synuclein level in PD patients did not differ from that in NC subjects. Similarly, the cortical GPR37 mRNA expression and CSF ecto-GPR37 levels in AD patients were also unaltered. Conclusion: GPR37 expression is increased in SN of sporadic PD patients. The ecto-GPR37 peptides are significantly increased in the CSF of PD patients, but not in AD patients. These results open perspectives and encourage further clinical studies to confirm the validity and utility of ecto-GPR37 as a potential PD biomarker., This work was supported by Ministerio de Ciencia, Innovación y Universidades–Agencia Estatal de Investigación/FEDER (SAF2017–87349-R and MDM-2017-0729) and ISCIII/FEDER (PIE14/00034 and PI19/00144), Generalitat de Catalunya (2017SGR1604, 2017SGR595), Fundació la Marató de TV3 (Grant 20152031) and FWO (SBO-140028). ERC consolidator grant (Progsy 649116), Stiftelsen för Strategisk Forskning and a Wallenberg Clinical Scholarship to PS. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Adenosine a2a receptors are upregulated in peripheral blood mononuclear cells from atrial fibrillation patients

  • Godoy-Marín, Héctor
  • Duroux, Romain
  • Jacobson, Kenneth A.
  • Soler, Concepció
  • Colino-Lage, Hildegard
  • Jiménez-Sábado, Verónica
  • Montiel, José
  • Hove-Madsen, Leif
  • Ciruela, Francisco
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia seen in clinical practice. While some clinical parameters may predict the transition from paroxysmal to persistent AF, the molecular mechanisms behind the AF perpetuation are poorly understood. Thus, oxidative stress, calcium overload and inflammation, among others, are believed to be involved in AF-induced atrial remodelling. Interestingly, adenosine and its receptors have also been related to AF development and perpetuation. Here, we investigated the expression of adenosine A2A receptor (A2AR) both in right atrium biopsies and peripheral blood mononuclear cells (PBMCs) from non-dilated sinus rhythm (ndSR), dilated sinus rhythm (dSR) and AF patients. In addition, plasma adenosine content and adenosine deaminase (ADA) activity in these subjects were also determined. Our results revealed increased A2AR expression in the right atrium from AF patients, as previously described. Interestingly, increased levels of adenosine content and reduced ADA activity in plasma from AF patients were detected. An increase was observed when A2AR expression was assessed in PBMCs from AF subjects. Importantly, a positive correlation (P=0.001) between A2AR expression in the right atrium and PBMCs was observed. Overall, these results highlight the importance of the A2AR in AF and suggest that the evaluation of this receptor in PBMCs may be potentially be useful in monitoring disease severity and the efficacy of pharmacological treatments in AF patients., This work was supported by Ministerio de Ciencia, Innovación y Universidades–Agencia Estatal de Investigación-FEDER-UE (SAF2017-87349-R MICIU/AEI/FEDER/UE and SAF207-88019- C3-1R MICIU/AEI/FEDER/UE) and ISCIII/FEDER (PIE14/00034 and CIBERCV-RD12/0042/0002), Generalitat de Catalunya (2017SGR1604 and 2017SGR1769), Fundació la Marató de TV3 (Grant 20152030/31) and NIDDK Intramural Res. (ZIADK31117).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Influence of sex on intracellular calcium homoeostasis in patients with atrial fibrillation

  • Herraiz-Martínez, Adela
  • Tarifa, Carmen
  • Jiménez-Sábado, Verónica
  • Llach, Anna
  • Godoy-Marín, Héctor
  • Colino-Lage, Hildegard
  • Nolla-Colomer, Carme
  • Casabella, Sergi
  • Izquierdo-Castro, Paloma
  • Benítez, Iván
  • Benítez, Raul
  • Roselló-Díez, Elena
  • Rodriguez-Font, E.
  • Viñolas, Xavier
  • Ciruela, Francisco
  • Cinca, Juan
  • Hove-Madsen, Leif
Aims Atrial fibrillation (AF) has been associated with intracellular calcium disturbances in human atrial myocytes, but little is known about the potential influence of sex and we here aimed to address this issue. Methods and results Alterations in calcium regulatory mechanisms were assessed in human atrial myocytes from patients without AF or with long-standing persistent or permanent AF. Patch-clamp measurements revealed that L-type calcium current (ICa) density was significantly smaller in males with than without AF (¿1.15¿±¿0.37 vs. ¿2.06¿±¿0.29 pA/pF) but not in females with AF (¿1.88¿±¿0.40 vs. ¿2.21¿±¿0.0.30 pA/pF). In contrast, transient inward currents (ITi) were more frequent in females with than without AF (1.92¿±¿0.36 vs. 1.10¿±¿0.19 events/min) but not in males with AF. Moreover, confocal calcium imaging showed that females with AF had more calcium spark sites than those without AF (9.8¿±¿1.8 vs. 2.2¿±¿1.9 sites/µm2) and sparks were wider (3.0¿±¿0.3 vs. 2.2¿±¿0.3 µm) and lasted longer (79¿±¿6 vs. 55¿±¿8 ms), favouring their fusion into calcium waves that triggers ITIs and afterdepolarizations. This was linked to higher ryanodine receptor phosphorylation at s2808 in women with AF, and inhibition of adenosine A2A or beta-adrenergic receptors that modulate s2808 phosphorylation was able to reduce the higher incidence of ITI in women with AF. Conclusion Perturbations of the calcium homoeostasis in AF is sex-dependent, concurring with increased spontaneous SR calcium release-induced electrical activity in women but not in men, and with diminished ICa density in men only., This work was supported by grants from The Spanish Ministry of Science Innovation and Universities [SAF2017-88019-C3-1-R MICIU /AEI/ FEDER /UE] to L.H.-M. [SAF2017-88019-C3-2-R MICIU /AEI/ FEDER /UE] to R.B. and [ SAF2017-87349-R MICIU /AEI/ FEDER /UE] to F.C.; and from the Spanish Ministry of Health and Consume, ISCIII, CIBERCV [CB16/11/00276] and Fondo Europeo de Desarrollo Regional (FEDER) to J.C., Fundació Marato TV3 [20152030/31] to L.H.-M./F.C. Also supported by ISC III [PIE14/00034] and IWT [SBO-140028] to F.C., a PhD grant [FPU/01250] to S.C., a PERIS grant from Generalitat de Catalunya to A.L. and [SGR2017-1769] to L.H.-M., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Ligand with two modes of interaction with the dopamine D2 receptor-an induced-fit mechanism of insurmountable antagonism

  • Ågren, Richard
  • Zeberg, Hugo
  • Stepniewski, Tomasz Maciej, 1988-
  • Free, R. Benjamin
  • Reilly, Sean W.
  • Luedtke, Robert R.
  • Århem, Peter
  • Ciruela, Francisco
  • Sibley, David R.
  • Mach, Robert H.
  • Selent, Jana
  • Nilsson, Johanna
  • Sahlholm, Kristoffer
A solid understanding of the mechanisms governing ligand binding is crucial for rational design of therapeutics targeting the dopamine D2 receptor (D2R). Here, we use G protein-coupled inward rectifier potassium (GIRK) channel activation in Xenopus oocytes to measure the kinetics of D2R antagonism by a series of aripiprazole analogues, as well as the recovery of dopamine (DA) responsivity upon washout. The aripiprazole analogues comprise an orthosteric and a secondary pharmacophore and differ by the length of the saturated carbon linker joining these two pharmacophores. Two compounds containing 3- and 5-carbon linkers allowed for a similar extent of recovery from antagonism in the presence of 1 or 100 μM DA (>25 and >90% of control, respectively), whereas recovery was less prominent (∼20%) upon washout of the 4-carbon linker compound, SV-III-130, both with 1 and 100 μM DA. Prolonging the coincubation time with SV-III-130 further diminished recovery. Curve-shift experiments were consistent with competition between SV-III-130 and DA. Two mutations in the secondary binding pocket (V91A and E95A) of D2R decreased antagonistic potency and increased recovery from SV-III-130 antagonism, whereas a third mutation (L94A) only increased recovery. Our results suggest that the secondary binding pocket influences recovery from inhibition by the studied aripiprazole analogues. We propose a mechanism, supported by in silico modeling, whereby SV-III-130 initially binds reversibly to the D2R, after which the drug-receptor complex undergoes a slow transition to a second ligand-bound state, which is dependent on secondary binding pocket integrity and irreversible during the time frame of our experiments., This study was supported by grants from Stiftelsen Lars Hiertas Minne, Åhlénstiftelsen, Karolinska Institutet Funds and Magnus Bergvalls stiftelse (to K.S.). K.S. received postdoctoral grants from the Swedish Brain Foundation and the Swedish Society of Medicine and is currently a fellow at the Wallenberg Center for Molecular Medicine at Umeå University. T.M.S. acknowledges financial support from the National Science Centre of Poland, project number 2017/27/N/NZ2/02571. J.S. received financial support from the Instituto de Salud Carlos III FEDER (PI15/00460 & PI18/00094) and the NEURON-ERANET (AC18/00030). F.C. was supported by FEDER/Ministerio de Ciencia, Innovación y Universidades–Agencia Estatal de Investigación (SAF2017-87349-R) and the Catalan government (2017 SGR 1604). R.B.F. and D.R.S. are supported by the National Institutes of Health, National Institute of Neurological Disorders and Stroke-Intramural Research Program (ZIA NS002263). We would like to thank Brittney Miller and Martin Dalefield for excellent technical assistance.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Ecto-GPR37: a potential biomarker for Parkinson's disease

  • Morató, Xavier
  • Garcia-Esparcia, Paula
  • Argerich, Josep
  • Llorens, Franc
  • Zerr, Inga
  • Paslawski, Wojciech
  • Borràs, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Petäjä-Repo, Ulla E.
  • Fernández-Dueñas, Víctor
  • Ferrer, Isidre
  • Svenningsson, Per
  • Ciruela, Francisco
Objective: α-Synuclein has been studied as a potential biomarker for Parkinson's disease (PD) with no concluding results. Accordingly, there is an urgent need to find out reliable specific biomarkers for PD. GPR37 is an orphan G protein-coupled receptor that toxically accumulates in autosomal recessive juvenile parkinsonism. Here, we investigated whether GPR37 is upregulated in sporadic PD, and thus a suitable potential biomarker for PD. Methods: GPR37 protein density and mRNA expression in postmortem substantia nigra (SN) from PD patients were analysed by immunoblot and RT-qPCR, respectively. The presence of peptides from the N-terminus-cleaved domain of GPR37 (i.e. ecto-GPR37) in human cerebrospinal fluid (CSF) was determined by liquid chromatography-mass spectrometric analysis. An engineered in-house nanoluciferase-based immunoassay was used to quantify ecto-GPR37 in CSF samples from neurological control (NC) subjects, PD patients and Alzheimer's disease (AD) patients. Results: GPR37 protein density and mRNA expression were significantly augmented in sporadic PD. Increased amounts of ecto-GPR37 peptides in the CSF samples from PD patients were identified by mass spectrometry and quantified by the in-house ELISA method. However, the CSF total α-synuclein level in PD patients did not differ from that in NC subjects. Similarly, the cortical GPR37 mRNA expression and CSF ecto-GPR37 levels in AD patients were also unaltered. Conclusion: GPR37 expression is increased in SN of sporadic PD patients. The ecto-GPR37 peptides are significantly increased in the CSF of PD patients, but not in AD patients. These results open perspectives and encourage further clinical studies to confirm the validity and utility of ecto-GPR37 as a potential PD biomarker., This work was supported by Ministerio de Ciencia, Innovación y Universidades–Agencia Estatal de Investigación/FEDER (SAF2017–87349-R and MDM-2017-0729) and ISCIII/FEDER (PIE14/00034 and PI19/00144), Generalitat de Catalunya (2017SGR1604, 2017SGR595), Fundació la Marató de TV3 (Grant 20152031) and FWO (SBO-140028). ERC consolidator grant (Progsy 649116), Stiftelsen för Strategisk Forskning and a Wallenberg Clinical Scholarship to PS. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Control of glutamate release by complexes of adenosine and cannabinoid receptors

  • Köfalvi, Attila
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Cordomí Montoya, Arnau|||0000-0002-3848-2928
  • Cai, Ning-Sheng
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Ferreira, Samira G.
  • Guixà González, Ramon|||0000-0003-0397-9800
  • Sánchez Soto, Marta
  • Yano, Hideaki
  • Casadó-Anguera, Verònica|||0000-0001-8532-2954
  • Cunha, Rodrigo A.
  • Sebastião, Ana Maria
  • Ciruela, Francisco|||0000-0003-0832-3739
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Casadó, Vicent|||0000-0002-1764-3825
  • Ferré, Sergi|||0000-0002-1747-1779
It has been hypothesized that heteromers of adenosine A receptors (A2AR) and cannabinoid CB receptors (CB1R) localized in glutamatergic nerve terminals mediate the integration of adenosine and endocannabinoid signaling involved in the modulation of striatal excitatory neurotransmission. Previous studies have demonstrated the existence of A2AR-CB1R heteromers in artificial cell systems. A dependence of A2AR signaling for the Gi protein-mediated CB1R signaling was described as one of its main biochemical characteristics. However, recent studies have questioned the localization of functionally significant A2AR-CB1R heteromers in striatal glutamatergic terminals. Using a peptide-interfering approach combined with biophysical and biochemical techniques in mammalian transfected cells and computational modeling, we could establish a tetrameric quaternary structure of the A2AR-CB1R heterotetramer. This quaternary structure was different to the also tetrameric structure of heteromers of A2AR with adenosine A receptors or dopamine D receptors, with different heteromeric or homomeric interfaces. The specific quaternary structure of the A2A-CB1R, which depended on intermolecular interactions involving the long C-terminus of the A2AR, determined a significant A2AR and Gs protein-mediated constitutive activation of adenylyl cyclase. Using heteromer-interfering peptides in experiments with striatal glutamatergic terminals, we could then demonstrate the presence of functionally significant A2AR-CB1R heteromers with the same biochemical characteristics of those studied in mammalian transfected cells. First, either an A2AR agonist or an A2AR antagonist allosterically counteracted Gi-mediated CB1R agonist-induced inhibition of depolarization-induced glutamate release. Second, co-application of both an A2AR agonist and an antagonist cancelled each other effects. Finally, a CB1R agonist inhibited glutamate release dependent on a constitutive activation of A2AR by a canonical Gs-Gi antagonistic interaction at the adenylyl cyclase level. We demonstrate that the well-established cannabinoid-induced inhibition of striatal glutamate release can mostly be explained by a CB1R-mediated counteraction of the A2AR-mediated constitutive activation of adenylyl cyclase in the A2AR-CB1R heteromer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A-Dopamine D Receptor Heterotetramers and Adenylyl Cyclase

  • Ferré, Sergi|||0000-0002-1747-1779
  • Bonaventura, Jordi
  • Zhu, Wendy
  • Hatcher-Solis, Candice
  • Taura, Jaume
  • Quiroz, César
  • Cai, Ning-Sheng
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Casadó-Anguera, Verònica|||0000-0001-8532-2954
  • Kravitz, Alexxai V.
  • Thompson, Kimberly R.
  • Tomasi, Dardo G.
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Cordomí Montoya, Arnau|||0000-0002-3848-2928
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Lluís, Carme
  • Dessauer, Carmen W.
  • Volkow, Nora|||0000-0001-6668-0908
  • Casadó, Vicent|||0000-0002-1764-3825
  • Ciruela, Francisco|||0000-0003-0832-3739
  • Logothetis, Diomedes E.
  • Zwilling, Daniel
The central adenosine system and adenosine receptors play a fundamental role in the modulation of dopaminergic neurotransmission. This is mostly achieved by the strategic co-localization of different adenosine and dopamine receptor subtypes in the two populations of striatal efferent neurons, striatonigral and striatopallidal, that give rise to the direct and indirect striatal efferent pathways, respectively. With optogenetic techniques it has been possible to dissect a differential role of the direct and indirect pathways in mediating "Go" responses upon exposure to reward-related stimuli and "NoGo" responses upon exposure to non-rewarded or aversive-related stimuli, respectively, which depends on their different connecting output structures and their differential expression of dopamine and adenosine receptor subtypes. The striatopallidal neuron selectively expresses dopamine D receptors (D2R) and adenosine A receptors (A2AR), and numerous experiments using multiple genetic and pharmacological in vitro, in situ and in vivo approaches, demonstrate they can form A2AR-D2R heteromers. It was initially assumed that different pharmacological interactions between dopamine and adenosine receptor ligands indicated the existence of different subpopulations of A2AR and D2R in the striatopallidal neuron. However, as elaborated in the present essay, most evidence now indicates that all interactions can be explained with a predominant population of striatal A2AR-D2R heteromers forming complexes with adenylyl cyclase subtype 5 (AC5). The A2AR-D2R heteromer has a tetrameric structure, with two homodimers, which allows not only multiple allosteric interactions between different orthosteric ligands, agonists, and antagonists, but also the canonical Gs-Gi antagonistic interaction at the level of AC5. We present a model of the function of the A2AR-D2R heterotetramer-AC5 complex, which acts as an integrative device of adenosine and dopamine signals that determine the excitability and gene expression of the striatopallidal neurons. The model can explain most behavioral effects of A2AR and D2R ligands, including the psychostimulant effects of caffeine. The model is also discussed in the context of different functional striatal compartments, mainly the dorsal and the ventral striatum. The current accumulated knowledge of the biochemical properties of the A2AR-D2R heterotetramer-AC5 complex offers new therapeutic possibilities for Parkinson's disease, schizophrenia, SUD and other neuropsychiatric disorders with dysfunction of dorsal or ventral striatopallidal neurons.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Influence of sex on intracellular calcium homoeostasis in patients with atrial fibrillation

  • Herraiz-Martínez, Adela
  • Tarifa, Carmen|||0000-0001-8954-6058
  • Jiménez-Sábado, Verónica|||0000-0001-7720-988X
  • Llach, Anna|||0000-0002-7486-1079
  • Godoy-Marín, Hector|||0000-0002-1534-6309
  • Colino-Lage, Hildegard|||0000-0002-8290-6070
  • Nolla-Colomer, Carme|||0000-0002-7681-3556
  • Casabella Ramón, Sergi|||0000-0001-7597-350X
  • Izquierdo-Castro, Paloma|||0000-0003-1494-5665
  • Benitez, Ivan David|||0000-0002-3558-5948
  • Benítez, Raúl|||0000-0002-8782-9406
  • Roselló-Díez, Elena|||0000-0003-2258-3246
  • Rodríguez-Font, Enrique|||0000-0001-5895-4219
  • Viñolas, Xavier|||0000-0002-8243-1271
  • Ciruela, Francisco|||0000-0003-0832-3739
  • Cinca, Juan|||0000-0003-4819-4265
  • Madsen, Leif Hove|||0000-0001-5493-3998
Atrial fibrillation (AF) has been associated with intracellular calcium disturbances in human atrial myocytes, but little is known about the potential influence of sex and we here aimed to address this issue. Alterations in calcium regulatory mechanisms were assessed in human atrial myocytes from patients without AF or with long-standing persistent or permanent AF. Patch-clamp measurements revealed that L-type calcium current (I ) density was significantly smaller in males with than without AF (-1.15 ± 0.37 vs. -2.06 ± 0.29 pA/pF) but not in females with AF (-1.88 ± 0.40 vs. -2.21 ± 0.0.30 pA/pF). In contrast, transient inward currents (I ) were more frequent in females with than without AF (1.92 ± 0.36 vs. 1.10 ± 0.19 events/min) but not in males with AF. Moreover, confocal calcium imaging showed that females with AF had more calcium spark sites than those without AF (9.8 ± 1.8 vs. 2.2 ± 1.9 sites/µm 2) and sparks were wider (3.0 ± 0.3 vs. 2.2 ± 0.3 µm) and lasted longer (79 ± 6 vs. 55 ± 8 ms), favouring their fusion into calcium waves that triggers I s and afterdepolarizations. This was linked to higher ryanodine receptor phosphorylation at s2808 in women with AF, and inhibition of adenosine A or beta-adrenergic receptors that modulate s2808 phosphorylation was able to reduce the higher incidence of I in women with AF. Perturbations of the calcium homoeostasis in AF is sex-dependent, concurring with increased spontaneous SR calcium release-induced electrical activity in women but not in men, and with diminished I density in men only. This work was supported by grants from The Spanish Ministry of Science Innovation and Universities [.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Remote local photoactivation of morphine produces analgesia without opioid-related adverse effects

  • López Cano, Marc|||0000-0001-8885-3726
  • Font Inglès, Joan|||0000-0001-8416-1909
  • Aso, Ester|||0000-0003-1836-1747
  • Sahlholm, Kristoffer|||0000-0001-6536-1972
  • Cabré Segura, Gisela|||0000-0003-3104-3364
  • Giraldo, Jesús|||0000-0001-7082-4695
  • De Koninck, Yves|||0000-0002-5779-9330
  • Hernando, Jordi|||0000-0002-1126-4138
  • Llebaria, Amadeu|||0000-0002-8200-4827
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Ciruela, Francisco|||0000-0003-0832-3739
Background and Purpose: Opioid-based drugs are the gold standard medicines for pain relief. However, tolerance and several side effects (i.e. constipation and dependence) may occur upon chronic opioid administration. Photopharmacology is a promising approach to improve the benefit/risk profiles of these drugs. Thus, opioids can be locally activated with high spatiotemporal resolution, potentially minimizing systemic-mediated adverse effects. Here, we aimed at developing a morphine photo-derivative (photocaged morphine), which can be activated upon light irradiation both in vitro and in vivo. Experimental Approach: Light-dependent activity of pc-morphine was assessed in cell-based assays (intracellular calcium accumulation and electrophysiology) and in mice (formalin animal model of pain). In addition, tolerance, constipation and dependence were investigated in vivo using experimental paradigms. Key results: In mice, pc-morphine was able to elicit antinociceptive effects, both using external light-irradiation (hind paw) and spinal cord implanted fibre-optics. In addition, remote morphine photoactivation was devoid of common systemic opioid-related undesired effects, namely, constipation, tolerance to the analgesic effects, rewarding effects and naloxone-induced withdrawal. Conclusion and Implications: Light-dependent opioid-based drugs may allow effective analgesia without the occurrence of tolerance or the associated and severe opioid-related undesired effects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Optical control of adenosine A3 receptor function in psoriasis

  • López Cano, Marc|||0000-0001-8885-3726
  • Filgaira, Ingrid|||0000-0002-9886-3925
  • Nolen, Ernest G.
  • Cabré Segura, Gisela|||0000-0003-3104-3364
  • Hernando, Jordi|||0000-0002-1126-4138
  • Tosh, Dilip K.
  • Jacobson, Kenneth A.|||0000-0001-8104-1493
  • Soler, Concepció|||0000-0001-6502-5012
  • Ciruela, Francisco|||0000-0003-0832-3739
Psoriasis is a chronic and relapsing inflammatory skin disease lacking a cure that affects approximately 2% of the population. Defective keratinocyte proliferation and differentiation, and aberrant immune responses are major factors in its pathogenesis. Available treatments for moderate to severe psoriasis are directed to immune system causing systemic immunosuppression over time, and thus concomitant serious side effects (i.e. infections and cancer) may appear. In recent years, the G protein-coupled A receptor (AR) for adenosine has been suggested as a novel and very promising therapeutic target for psoriasis. Accordingly, selective, and high affinity AR agonists are known to induce robust anti-inflammatory effects in animal models of autoimmune inflammatory diseases. Here, we demonstrated the efficacy of a selective AR agonist, namely MRS5698, in preventing the psoriatic-like phenotype in the IL-23 mouse model of psoriasis. Subsequently, we photocaged this molecule with a coumarin moiety to yield the first photosensitive AR agonist, MRS7344, which in photopharmacological experiments prevented the psoriatic-like phenotype in the IL-23 animal model. Thus, we have demonstrated the feasibility of using a non-invasive, site-specific, light-directed approach to psoriasis treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Remote control of movement disorders using a photoactive adenosine A 2A receptor antagonist

  • Taura, Jaume
  • Nolen, Ernest G.
  • Cabré Segura, Gisela|||0000-0003-3104-3364
  • Hernando, Jordi|||0000-0002-1126-4138
  • Squarcialupi, Lucia
  • López Cano, Marc|||0000-0001-8885-3726
  • Jacobson, Kenneth A.|||0000-0001-8104-1493
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Ciruela, Francisco|||0000-0003-0832-3739
G protein-coupled adenosine receptors are promising therapeutic targets for a wide range of neuropathological conditions, including Parkinson's disease (PD). However, the ubiquity of adenosine receptors and the ultimate lack of selectivity of certain adenosine-based drugs have frequently diminished their therapeutic use. Photopharmacology is a novel approach that allows the spatiotemporal control of receptor function, thus circumventing some of these limitations. Here, we aimed to develop a light-sensitive caged adenosine A receptor (A R) antagonist to photocontrol movement disorders. We synthesized MRS7145 by blocking with coumarin the 5-amino position of the selective A R antagonist SCH442416, which could be photoreleased upon violet light illumination (405 nm). First, the light-dependent pharmacological profile of MRS7145 was determined in A R-expressing cells. Upon photoactivation, MRS7145 precluded A R ligand binding and agonist-induced cAMP accumulation. Next, the ability of MRS7145 to block A R in a light-dependent manner was assessed in vivo. To this end, A R antagonist-mediated locomotor activity potentiation was evaluated in brain (striatum) fiber-optic implanted mice. Upon irradiation (405 nm) of the dorsal striatum, MRS7145 induced significant hyperlocomotion and counteracted haloperidol-induced catalepsy and pilocarpine-induced tremor. Finally, its efficacy in reversing motor impairment was evaluated in a PD animal model, namely the hemiparkinsonian 6-hydroxydopamine (6-OHDA)-lesioned mouse. Photo-activated MRS7145 was able to potentiate the number of contralateral rotations induced by L-3,4-dihydroxyphenylalanine (L-DOPA). Overall, MRS7145 is a new light-operated A R antagonist with potential utility to manage movement disorders, including PD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Adenosine a2a receptors are upregulated in peripheral blood mononuclear cells from atrial fibrillation patients

  • Godoy-Marín, Hector|||0000-0002-1534-6309
  • Duroux, Romain|||0000-0001-7099-1469
  • Jacobson, Kenneth A.|||0000-0001-8104-1493
  • Soler, Concepció|||0000-0001-6502-5012
  • Colino-Lage, Hildegard|||0000-0002-8290-6070
  • Jiménez-Sábado, Verónica|||0000-0001-7720-988X
  • Montiel, José|||0000-0002-3791-5218
  • Madsen, Leif Hove|||0000-0001-5493-3998
  • Ciruela, Francisco|||0000-0003-0832-3739
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia seen in clinical practice. While some clinical parameters may predict the transition from paroxysmal to persistent AF, the molecular mechanisms behind the AF perpetuation are poorly understood. Thus, oxidative stress, calcium overload and inflammation, among others, are believed to be involved in AF-induced atrial remodelling. Interestingly, adenosine and its receptors have also been related to AF development and perpetuation. Here, we investigated the expression of adenosine A2A receptor (A2AR) both in right atrium biopsies and peripheral blood mononuclear cells (PBMCs) from non-dilated sinus rhythm (ndSR), dilated sinus rhythm (dSR) and AF patients. In addition, plasma adenosine content and adenosine deaminase (ADA) activity in these subjects were also determined. Our results revealed increased A2AR expression in the right atrium from AF patients, as previously described. Interestingly, increased levels of adenosine content and reduced ADA activity in plasma from AF patients were detected. An increase was observed when A2AR expression was assessed in PBMCs from AF subjects. Importantly, a positive correlation (P=0.001) between A2AR expression in the right atrium and PBMCs was observed. Overall, these results highlight the importance of the A2AR in AF and suggest that the evaluation of this receptor in PBMCs may be potentially be useful in monitoring disease severity and the efficacy of pharmacological treatments in AF patients.